갑상선 유두암의 예후 예측 인자로서 BRAFV600E 돌연변이의 역할

권택주; 백진오; 이지연; 강진구; 황승욱; 김완욱; 박호용; 정지윤; 박지영; 정진향

추천

검색

자료유형: 학술저널

저자정보: 권택주 백진오 이지연 강진구 황승욱 김완욱 박호용 정지윤 박지영 정진향

저널정보: 대한갑상선-내분비외과학회 The Journal of Endocrine Surgery The Journal of Endocrine Surgery 제14권 제3호

발행연도: 2014.1

수록면: 150 - 155 (6page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Purpose: Papillary thyroid carcinoma (PTC) is the most common malignant tumor of the thyroid and BRAFV600E mutation is the most frequent genetic alteration in PTC. BRAFV600Emutation has been demonstrated as a prognostic biomarker for prediction of poor clinicopathological outcomes, such as increased incidence of extrathyroidal extension, lymph node metastasis, and advanced stage. However, there is conflicting literature regarding the association of BRAFV600E mutation and aggressive clinicopathological features. In this study, we investigated the prevalence of BRAFV600E mutation in PTC and determined the association of BRAF mutation with indicators of poor prognosis for PTC.Methods: We reviewed 1009 patients with PTC, who underwent thyroid surgery at Kyungpook National University Hospital between January 2013 and March 2014. BRAFV600E mutation analysis was performed using real-time polymerase chain reaction based amplification of DNA extracted from paraffin-embedded tumor specimens. Results: BRAFV600E mutation was detected in 863 (85.5%) patients. In univariate analysis, histologic subtype, extrathyroidal extension, and advanced stage showed significant association with BRAFV600E mutation. In addition, concurrent Hashimoto’s thyroiditis showed an association with low prevalence of BRAFV600E mutation. However, no stati-stically significant association was observed for age, gender, multifocal or bilateral tumor, and lymph node metastasis. Multivariate analysis showed an independent association of extrathyroidal extension with BRAFV600E mutation.Conclusion: In this study, extrathyroidal extension of PTC is an independent prognostic factor associated with BRAFV600E mutation status. However, conduct of further large scale studies with long term follow up is required before the BRAF mutation can be conclusively recommended as a prognostic biomarker.

#갑상선 유두암 #BRAF 돌연변이 #예후인자 #Papillary thyroid carcinoma #BRAF mutation #Prognosis

참고문헌 (25)

참고문헌 신청

Adeniran AJ / 2006 / Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinoma

Cahill S / 2007 / Effect of BRAFV600E mutation on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model / Mol Cancer 6 : 21 ~

DeLellis RA / 2006 / Pathology and genetics of thyroid carcinoma / J Surg Oncol 94 : 662 ~ 669

Edge SB / 2010 / AJCC cancer staging manual / Springer-Verlag

Fugazzola L / 2004 / BRAF mutations in an Italian cohort of thyroid cancers / Clin Endocrinol 61 : 239 ~ 243